



Intravacc Corporate Vaccsheet



Mission

To reduce human disease through innovative vaccine technology

Vision

To partner with governmental agencies, NGOs and private entities to help to reduce the burden of disease

Intravacc B.V.

- Founded in 2013
- Private company since 2021
- HQ at Utrecht Science Park Bilthoven, The Netherlands
- Experts in vaccinology
- 11 patent families
- 2000+ m2 state-of-the-art facilities, incl BSL-2/3 & GMP
- ISO 9001 and 14001 certified
- ~130 highly qualified employees
- 50+ customers worldwide
- 300+ scientific publications in peer reviewed journals

Board of Directors

- Dr. Jan Groen, CEO
- Ms. Nathalie Laarakker, CFO

Supervisory Board


- Mr. Nico Oudendijk (Chair)
- Mr. Bruno Bruins
- Dr. Karin Dorrepaal

Scientific Advisory Board

- Dr. Marien de Jonge
- Dr. Harry Flore
- Prof. dr. Anke Huckriede
- Dr. Paul Wichgers Schreur
- Dr. Paul Oostvogel M.D.
- Prof. dr. Evelien Smits

Company profile

Intravacc B.V. is a leading global contract development and manufacturing organization (CDMO) specializing in innovative vaccines for infectious diseases and therapeutic cancer vaccines. The company is privately held and located in Bilthoven in the Netherlands. As an established CDMO in the vaccine industry, Intravacc has developed, out-licensed and transferred its technology, procedures and know-how worldwide, including vaccines for polio, measles, DPT, Hib and influenza. Intravacc has a wide range of expertise, bridging the gap between discovery and pilot-scale GMP production, through to phase I/II clinical trials.



With our wide range of expertise in the vaccine industry Intravacc is the one-stop-shop to mature your lead to a first-in-humans clinical study. In addition we can also provide CDMO services to push your vaccine candidate forward.



Figure 1: Vaccine platforms

Platforms, Services & Products

Intravacc offers 4 platforms for vaccine development. The patented cell based, OMV, iBoost and conjugation platforms have already been tested in (pre)clinical studies, and two products (a cell and a conjugate vaccine) are on the market through our partners. These platforms can be out-licensed on a non-exclusive basis. In addition, Intravacc offers CDMO services and vaccine products for licensing.




Figure 2: Services provided by Intravacc

Vaccine	Target	Platform	Stage			
			Development	Pre-clinical	Phase I	Phase II
Avacc 17 [®]	Hib	Conjugation	Marketed			
Avacc 19 [®]	RSV	Cell	Marketed			
Avacc 13 [®]	MenB	OMV	Marketed			
Avacc 10 [®]	Covid-19	OMV	Marketed			
Avacc 7 [®]	Lyme	OMV	Marketed			
Avacc 3 [®]	Pertussis	OMV	Marketed			
Avacc 2 [®]	HFMD	Cell	Marketed			
Avacc 23 [®]	Bladder cancer	iBoost	Marketed			

Figure 3: IntrAvacc vaccine product pipeline, open for licensing